Zealand Pharma A/S (CPH: ZEAL)
Denmark
· Delayed Price · Currency is DKK
728.00
-28.50 (-3.77%)
Dec 20, 2024, 4:59 PM CET
Zealand Pharma Revenue
Zealand Pharma had revenue of 4.42M DKK in the quarter ending September 30, 2024, a decrease of -98.51%. This brings the company's revenue in the last twelve months to 76.87M, down -77.62% year-over-year. In the year 2023, Zealand Pharma had annual revenue of 342.79M with 229.65% growth.
Revenue (ttm)
76.87M
Revenue Growth
-77.62%
P/S Ratio
n/a
Revenue / Employee
257.95K
Employees
253
Market Cap
51.43B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 342.79M | 238.80M | 229.65% |
Dec 31, 2022 | 103.99M | -4.56M | -4.20% |
Dec 31, 2021 | 108.55M | -83.46M | -43.47% |
Dec 31, 2020 | 192.00M | 150.67M | 364.52% |
Dec 31, 2019 | 41.33M | 3.36M | 8.84% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Novo Nordisk A/S | 270.58B |
Coloplast A/S | 27.03B |
Genmab A/S | 19.84B |
Demant A/S | 22.84B |
H. Lundbeck A/S | 21.44B |
H. Lundbeck A/S | 21.44B |
ALK-Abelló A/S | 5.38B |
Ambu A/S | 5.39B |
Zealand Pharma News
- 1 day ago - Zealand Pharma CEO says Novo's CagriSema data supports monotherapy approach to cagrilintide - Reuters
- 1 day ago - FDA drug rejection hits Zealand Pharma shares - Financial Times
- 2 days ago - FDA rejects Zealand Pharma's drug for short bowel syndrome - Seeking Alpha
- 2 days ago - US FDA declines to approve Zealand Pharma's bowel disease drug - Reuters
- 2 days ago - U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome - GlobeNewsWire
- 2 days ago - Zealand Pharma And Eli Lilly: Strategic Focus On Weight Management And Future Outlook - Seeking Alpha
- 5 days ago - Zealand Pharma A/S 2024 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 11 days ago - Zealand Pharma starts Phase 2b trial for obesity drug candidate petrelintide - Reuters